Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome
Angelo Valerio Marzano(University of Milan), Massimo Cugno(University of Milan), Emiliano Antiga(University of Florence), Marzia Caproni(Azienda Usl Toscana Centro), Pier Luigi Meroni(IRCCS Istituto Auxologico Italiano), C. Crosti(University of Milan), Daniele Fanoni(University of Milan), Pietro Quaglino(Department of Medical Sciences)
Cited by 239
Related Papers
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
|Journal of Thrombosis and Haemostasis|2006|7.1k
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
|JAMA Dermatology|2015|452